Italian pharmaceutical company Alfasigma S.p.A. announced on Tuesday that it has entered into an agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its subsidiaries, expanding its specialty pharmaceutical portfolio and international presence.

The acquisition will add Nordic Pharma's rheumatoid arthritis business, led by the Nordimet methotrexate franchise, to Alfasigma's rheumatology portfolio, which includes Jyseleca.

The transaction is expected to add approximately EUR190m in 2025 revenue, strengthen Alfasigma's presence in Europe through direct operations in 18 countries and establish commercial platforms in Canada and Japan.

Nordic Pharma also brings portfolios in women's health, critical care and ophthalmology, along with 265 employees with specialist capabilities.

This acquisition supports Alfasigma's M&A-led growth strategy focused on specialty and rare diseases, particularly immunology and gastroenterology.

Financial terms were not disclosed. The transaction remains subject to customary closing conditions, including required regulatory clearances.